References
- Smith SR, Weissman NJ, Anderson CM, et al. Behavioral modification and lorcaserin for overweight and obesity management (BLOOM) study group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010 Jul 15;363(3):245–256.
- Fidler MC, Sanchez M, Raether B, et al., BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011 Oct;96(10):3067–3077.
- O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;Jul;20(7):1426–1436.
- Bohula EA, Scirica BM, Inzucchi SE, et al. CAMELLIA-TIMI 61 steering committee investigators. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet. 2018 Nov 24;392(10161):2269–2279.
- Sharretts J, Galescu O, Gomatam S, et al. Cancer risk associated with lorcaserin- the FDA’s review of the CAMELLIA-TIMI 61 trial. N Engl J Med. 2020 Sep 10;383(11):1000–1002.
- Greenway FL, Shanahan W, Fain R, et al. Safety and tolerability review of lorcaserin in clinical trials. Clin Obes. 2016 Oct;6(5):285–295.
- Tchang BV, Abel B, Zecca C, et al. An up-to-date evaluation of lorcaserin hydrochloride for the treatment of obesity. Expert Opin Pharmacother. 2020;21:1, 21–28.
- Fujioka, Perdomo C, Malhotra M. Effect of lorcaserin on weight reduction in persons with obstructive sleep apnea: a combined subgroup analysis from three randomized, controlled clinical trials. Obesity Sci Pract. 2019;5:238–245.
- Fujioka K. Safety and tolerability of medications approved for chronic weight management. Obesity. 2015;2015(23 Suppl):S7–S11.
- Bays H, Perdomo C, Nikonova E, et al. Lorcaserin and metabolic disease: weight loss dependent and independent effects. Obesity Sci Pract. 2018;4:499–505.
- Burke LK, Ogunnowo-Bada E, Georgescu T, et al. Lorcaserin improves glycemic control via a melanocortin neurocircuit. Mol Metab. 2017 Oct;6(10):1092–1102.
- Tcheugui JBE, Ahima R. The CAMELLIA-TIMI-61 trial; 2019. [cited 2020 Sep 11]. Available from: https://www.acc.org/latest-in-cardiology/articles/2019/07/24/06/28/the-camellia-timi-61-trial
- Bohula EA, Wiviott SD, McGuire DK, et al. CAMELLIA–TIMI 61 Steering Committee and Investigators. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. N Engl J Med. 2018 Sep 20;379(12):1107–1117.
- Health Canada. Regulatory decision summary- lorcaserin hydrochloride. [cited 2020 Sep 09]. Available from: https://hprrps.hres.ca/reg-content/regulatory-decision-summarydetailTwo.php?lang=en&linkID=RDS00370
- European Medicines Agency. Withdawal of the marketing authorisation application for Belviq (lorcaserin). [cited 2020 Sep 09]. Available from: https://www.ema.europa.eu/en/documents/medicine-qa/questionsanswers-withdrawal-marketing-authorisation-application-belviq_en.pdf
- Smith SR, Garvey WT, Greenway FL, et al. Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study. Obesity (Silver Spring). 2017;25(5):857–865.
- Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review. BMC Med. 2016;14:191.
- Dunlop J, Watts SW, Barrett JE, et al. Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist. J Pharmacol Exp Ther. 2011 Jun;337(3):673–680.
- Farr OM, Upadhyay J, Gavrieli A, et al. Lorcaserin administration decreases activation of brain centers in response to food cues and these emotion- and salience-related changes correlate with weight loss effects: a 4-week-long randomized, placebo-controlled, double-blind clinical trial. Diabetes. 2016 Oct;65(10):2943–2953.
- Wold EA, Wild CT, Cunningham KA, et al. Targeting the 5-HT2C receptor in biological context and the current state of 5-HT2C receptor ligand development. Curr Top Med Chem. 2019;19(16):1381–1398.
- García-Cárceles J, Decara JM, Vázquez-Villa H, et al. A positive allosteric modulator of the serotonin 5-HT2c receptor for obesity. J Med Chem. 2017;60(23):9575–9584.
- Negus SS, Banks ML. Learning from lorcaserin: lessons from the negative clinical trial of lorcaserin to treat cocaine use disorder. Neuropsychopharmacol. 2020;45:1967–1973.